Hey, wait up Amgen and Mirati, Boehringer Ingelheim is joining the KRAS crowd as early success inspires rivals
It doesn’t take long for hot new cancer targets to attract a bustling field of rivals. Take KRAS, for example.
Today you can add Boehringer Ingelheim to the group with clinical-stage KRAS assets to boast about. Investigators presented their preclinical case for the oral KRAS inhibitor BI 1701963 in Boston today, and unveiled plans to go after a full slate of KRAS mutations in a move aimed beyond just G12C, where Amgen and Mirati are now vying for the lead with promising, but very early, lung cancer data.
This wasn’t exactly a secret, as Evercore ISI analyst Umer Raffat had flagged the clinical move a few weeks ago, but this was Boehringer Ingelheim’s chance to spotlight their strategy.
The research team at Boehringer has moved BI 1701963 — an SOS1 inhibitor — as a monotherapy as well as in combination with the MEK inhibitor Mekinist (trametinib) into Phase I for various KRAS mutations. That’s a well-defined combo opportunity for everyone contending for a piece of what many believe is a blockbuster new market in the making. And no one is waiting around to line up new shots on goal.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.